Viral Vector Manufacturing Industry is Subdued to Increase a Perfect Double-Digi

Posted by Shrikant Gadewar on January 22nd, 2020

Market Overview:

The global viral vector manufacturing market is expected to exhibit a strong 22.65% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The nreport forecasts a valuation of USD 319 million for the market by the end of the 2018-2023 forecast period. The report takes a close look at historical factors enabling growth of the viral vector manufacturing market and presents a detailed analysis of the market’s likely growth trajectory over the forecast period. The major drivers and restraints affecting the global viral vector manufacturing market are analyzed in detail in the report. The report also takes a look at the major competitive factors defining the viral vector manufacturing market’s competitive landscape and provides a profile of the leading players in the viral vector manufacturing market. Thus, the report provides a thorough look at the global viral vector manufacturing market through all sides and perspectives.

On the other hand, difficulties in producing viral vectors and the absence of the appropriate tools are likely to be the key restraints acting against the global Viral Vector Manufacturing Industry over the forecast period. Many companies in the global viral vector manufacturing market are taking steps to counter the difficulties in producing viral vectors and this area is likely to remain a hive of activity in the coming years. This has also resulted in strong growth prospects for companies that can develop effective viral vector manufacturing platforms and systems and sell them to clients in drug discovery applications.

Competitive Analysis:

•          Kaneka Eurogentec S.A.
•          REGENXBIO Inc
•          Cobra Biologics
•          Cell and Gene Therapy Catapult
•          Brammer Bio
•          FinVector Vision Therapies
•          uniQure N.V
•          Spark Therapeutics Inc
•          Oxford BioMedica
•          General Electric Company
•          Merck KGaA
•          Lonza

Segmentation:

•          The global viral vector manufacturing market is segmented on the basis of type, disease, application, end use, and region.
•          By type, the global viral vector manufacturing market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The retroviral vectors segment is further sub-segmented into lentiviral vectors and gamma-retroviral vectors. The retroviral vectors segment holds the largest share in the global viral vector manufacturing market. Retroviruses contain the enzyme reverse transcriptase, which enables easy assimilation into the host DNA. This has driven the demand for retroviral vectors. The adenoviral vectors segment is also expected to exhibit rapid growth over the forecast period.
•          By disease, the global viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and others.
•          By application, the market is segmented into gene therapy and vaccinology.
•          By end use, the global viral vector manufacturing market is segmented into pharma and biotech companies, research institutes, and others.

Regional Analysis:

The Americas is anticipated to dominate the global viral vector manufacturing market over the forecast period, foll